Drug profile · INN
glofitamab
COLUMVI
glofitamab (COLUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with Hoffmann-La Roche.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01FX28
Patents linked 0
Pipeline programs 17
News articles 1
Congress events 1
Drug details — glofitamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 17
- Data quality
- 0.83
Quick answer
glofitamab (COLUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with Hoffmann-La Roche.
Key facts
INN glofitamab
Brand COLUMVI
Mechanism B-lymphocyte antigen CD20 binding agent
Target B-lymphocyte antigen CD20
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX28
Originator Hoffmann-La Roche
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Congress & event coverage
- PresentationDIA
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is glofitamab?
glofitamab (COLUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with Hoffmann-La Roche.
What is the brand name for glofitamab?
COLUMVI is a marketed brand name for glofitamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.